A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Summary

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.

Timeline

Start

2024-01-08

Primary completion

2026-11-01

Completion

2027-11-01

Publications

• Greenman M, Bellone S, Demirkiran C, Max Philipp Hartwich T, Santin AD. Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer. Gynecol Oncol Rep. 2024 Jul 13;54:101459. doi: 10.1016/j.gore.2024.101459. eCollection 2024 Aug.

Drugs

Indications